Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)β’ Click on a phase to view related trials
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Akesobio Australia Pty Ltd
- Target Recruit Count
- 79
- Registration Number
- NCT05048056
- Locations
- πΊπΈ
AkesoBio Investigative Site 2003, Little Rock, Arkansas, United States
πΊπΈAkesoBio Investigative Site 2010, Canoga Park, California, United States
πΊπΈAkesoBio Investigative Site 2021, San Diego, California, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
- Conditions
- Advanced or Metastatic Solid Tumours
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Akesobio Australia Pty Ltd
- Target Recruit Count
- 66
- Registration Number
- NCT05021120
- Locations
- π¦πΊ
Ashford Cancer Centre Research, Adelaide, Australia
π¦πΊAustin Health, Melbourne, Australia
π¦πΊMonash Health, Melbourne, Australia
A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Akesobio Australia Pty Ltd
- Target Recruit Count
- 29
- Registration Number
- NCT04516564
- Locations
- π³πΏ
Christchurch Clinical Studies Trust, Christchurch, New Zealand
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Akesobio Australia Pty Ltd
- Target Recruit Count
- 38
- Registration Number
- NCT04349969
- Locations
- π¦πΊ
Blacktown Hospital, Sydney, New South Wales, Australia
π¦πΊICON Cancer Foundation, South Brisbane, Queensland, Australia
π¦πΊAshford Cancer Centre Research, Kurralta Park, South Australia, Australia
A Study of AK120 (IL-4RΞ±) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: AK120 or placebo- Part 2- Cohort 4Drug: AK120 or placebo- Part 1- Cohort 5Drug: AK120 or placebo- Part 1- Cohort 1Drug: AK120 or placebo- Part 2- Cohort 1Drug: AK120 or placebo- Part 2- Cohort 2Drug: AK120 or placebo- Part 1- Cohort 4Drug: AK120 or placebo- Part 1- Cohort 2Drug: AK120 or placebo- Part 1- Cohort 3Drug: AK120 or placebo- Part 2- Cohort 3
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Akesobio Australia Pty Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT04256174
- Locations
- π¦πΊ
Emeritus Sydney, Botany, New South Wales, Australia
π¦πΊEmeritus Melbourne, Camberwell, Victoria, Australia
π¦πΊCMAX Clinical Research, Adelaide, Australia
- Prev
- 1
- 2
- Next